GLP-1 Therapies Research Papers | Page 11 | OpenScience.ink

2 weeks ago • Hormones (Athens, Greece)

New diabetes medicines being developedAntidiabetic medications in the pipeline.

📖 Top 30% JournalArticle

2 weeks ago • Clinical, cosmetic and investigational dermatology

Safety of Energy-Based Treatments for Facial Aging Linked to GLP-1 Receptor Agonist Use in Different Skin TissuesEnergy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.

📖 Top 30% JournalArticle

2 weeks ago • Diabetes, metabolic syndrome and obesity : targets and therapy

Adherence and Persistence with Injectable Compared to Oral GLP-1 Treatments in People with Type 2 DiabetesAdherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis.

📖 Top 30% JournalArticle

2 weeks ago • Archives of medical science : AMS

GLP-1 receptor drugs and their effects on tendon healing: a review and combined analysisGLP-1 receptor agonists and tendon healing: a systematic review and meta-analysis.

📖 Top 30% JournalArticle

3 weeks ago • Expert opinion on pharmacotherapy

Drug treatments for MASLD and MASH: approved options, reused medicines, and new targeted drugsPharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates.

📖 Top 30% JournalArticle

3 weeks ago • Expert opinion on pharmacotherapy

Obesity treatment with oral medication for people who avoid injectionsObesity: oral therapy for those afraid of needles.

📖 Top 30% JournalArticle

3 weeks ago • Otolaryngologic clinics of North America

Thyroid Problems in the Age of Obesity and Diabetes Drugs That Lower Blood SugarThyroid Disease in the Era of Obesity and Glucagon-Like-Peptide-1 Agonists.

📖 Top 50% JournalArticle

3 weeks ago • Translational andrology and urology

Comparison of diabetes drugs and their links to new and repeated kidney stonesSodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review.

📖 Top 30% JournalArticle

3 weeks ago • Journal of Ayurveda and integrative medicine

Long-term metabolism control with GLP-1 receptor drugs: Combining Ayurvedic and medical viewsLong-term metabolic regulation in the era of GLP-1 receptor agonists: An integrative review of Ayurvedic and biomedical perspectives.

📖 Top 50% JournalArticle

3 weeks ago • Journal of molecular histology

Liraglutide helps obesity-related type 2 diabetes by changing immune cell cholesterol use and gene activity to boost anti-inflammatory cells and fat burningLiraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation.

📖 Top 30% JournalArticle

3 weeks ago • Cardiology

Semaglutide Use and Discussion in Obese Patients with Heart Failure and Normal Heart PumpingSemaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.

📖 Top 50% JournalArticle

3 weeks ago • Clinical nutrition ESPEN

Side Effects of Semaglutide Reported to the U.S. FDACharacterizing the adverse event profile of semaglutide: A comprehensive U.S. food and drug administration adverse event reporting system-based pharmacovigilance study.

📖 Top 30% JournalArticle

3 weeks ago • Clinics in dermatology

Metabolism and Skin Health: New Diabetes-Related Drugs as Immune and Metabolic Treatments for Obesity-Linked Skin ProblemsThe Metabolic-Dermatologic Axis: GLP-1/GIP Agonists as Emerging Immunometabolic Therapies for Obesity-Associated Skin Disease.

📖 Top 50% JournalArticle

3 weeks ago • Clinics in dermatology

Changes in Facial Appearance and Aging Linked to Ozempic Use"Ozempic Face" and Facial Aging.

📖 Top 50% JournalArticle

3 weeks ago • Disease-a-month : DM

Current use of GLP-1 drugs for treating substance abuse: A systematic reviewStatus Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.

📖 Top 50% JournalArticle

3 weeks ago • The American journal of cardiology

How Social and Economic Disadvantages Relate to Heart Failure Treatment Results with GLP-1 MedicinesAssociation between Socioeconomic Deprivation and Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure.

📖 Top 20% JournalArticle

3 weeks ago • Advances in medical sciences

Tirzepatide use, sticking to treatment, and dose increases in Polish patients facing high personal costsTirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.

📖 Top 30% JournalArticle

3 weeks ago • Expert review of clinical immunology

GLP-1 receptor agonists may help brain diseases by changing immune cells and reducing brain inflammationThe therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.

📖 Top 20% JournalArticle

3 weeks ago • Obesity science & practice

Preventing Weight Gain After Stopping Glucagon-Like Peptide-1 Treatment: A Small Randomized TrialPreventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.

📖 Top 30% JournalArticle

3 weeks ago • The journal of ECT

Managing Electroconvulsive Therapy in Patients Taking GLP-1 Diabetes Drugs: Balancing Safety, Treatment Following, and ConsistencyNavigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report.

📖 Top 50% JournalArticle

4 weeks ago • Journal of nephrology

Obesity’s Mixed Impact in Chronic Kidney DiseaseObesity in CKD: The Double-Edged Sword.

📖 Top 30% JournalArticle

4 weeks ago • Clinical nutrition ESPEN

Natural Foods That May Influence Weight Control by Affecting a Key Hormone ReceptorInsights into natural dietary components as indirect modulators of glucagon-like Peptide-1 receptor signaling in weight management.

📖 Top 30% JournalArticle

4 weeks ago • Obesity research & clinical practice

Changes over time in use of diabetes medications during pregnancy in Manitoba, Canada, 2015-2023Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015-2023.

📖 Top 20% JournalLetter

1 month ago • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

How Cell Recycling and Gene Regulation in Brain Hunger Centers May Explain Ongoing Obesity and Treatment ChallengesThe Autophagy-Epigenome Axis in Hypothalamic Neurons: A Unified Framework for Understanding Obesity Persistence and Therapeutic Resistance.

📖 Top 50% JournalArticle

3 weeks ago • International medical case reports journal

Severe Diabetic Ketoacidosis with Normal Blood Sugar After Poor Eating Linked to Semaglutide, Despite Stopping Empagliflozin: A Case ReportSevere Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report.

Case Reports

4 weeks ago • BMJ case reports

Persistent nausea linked to peptide injections containing retatrutide as a new health riskEmerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.

Case Reports

4 days ago • Endocrine

Blood sugar control and weight loss with combined basal insulin and GLP-1 treatments in type 2 diabetesGlycemic control and weight loss benefits of fixed-ratio combinations of basal insulins and GLP1 receptor agonists in type 2 diabetes: A systematic review and network meta-analysis.

Systematic Review

1 week ago • Psychological medicine

Semaglutide may influence decision-making between exploring and exploiting options in major depressionSemaglutide modulates explore/exploit decision-making in major depressive disorder: A randomized clinical trial.

Randomized Controlled Trial

2 days ago • Diabetology international

How Depression Levels Relate to Different Mental Health Paths During GIP and GLP-1 Receptor Agonist TreatmentsBaseline depressive-symptom severity and divergent psychological trajectories during GIP and/or GLP-1 receptor agonist therapy: a prospective ecological momentary assessment study.

📖 Top 50% JournalArticle

2 days ago • Journal of diabetes and metabolic disorders

Effectiveness and safety of semaglutide compared to placebo in adults with overweight or obesity without diabetesEfficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials.

📖 Top 50% JournalArticle

← prevpage 11 of 16next →